Casado, Carlos
Cepeda-Franco, Carmen
Pereira Arenas, Sheila
Suarez, Maria Dolores
Gómez-Bravo, Miguel Ángel
Alaminos, Miguel
Chato-Astrain, Jesús
Fernández-Muñoz, Beatriz
Campos-Cuerva, Rafael
Funding for this research was provided by:
Universidad de Sevilla (VIIPPIT-2022-II.4)
Instituto de Salud Carlos III (DTS19/00089)
Fundación Para La Innovación Y La Prospectiva En Salud En España (3728-20)
Article History
Received: 28 April 2024
Accepted: 16 August 2024
First Online: 21 August 2024
Competing interests
: Rafael Campos Cuerva, Beatriz Fernández Muñoz, Carmen Cepeda Franco and Miguel Ángel Gómez Bravo are authors of a patent for the use of NFAH as a hemostatic agent (US 17/045,661; EP19717461.8; PCT/EP2019/058822). Miguel Alaminos is authors of patent for NFAH (n° application Spanish Patent Office: 200930943). Carlos Casado, Sheila Pereira Arenas, María Dolores Suarez and Jesús Chato Astrain declare that they have no conflict of interest.